Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03988439 · ClinicalTrials.gov registry record · Phase 4
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
A Phase 4 study of Psoriasis, sponsored by Bausch Health Americas.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 45
- Enrollment target
- 9
- Study locations
NCT03988439 is a Phase 4 study of Psoriasis that is actively recruiting participants, run by Bausch Health Americas. The registered enrollment target is 45 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (91% lower). The trial reports 9 study locations across 7 states.
The verdict
NCT03988439, a Phase 4 study of Psoriasis, is actively recruiting participants, sponsored by Bausch Health Americas.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 45 participants
- Enrollment target
- 9
- Study locations
Study Summary
This study is to evaluate the safety, the systemic exposure, and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-118 lotion in pediatric participants with moderate to severe plaque psoriasis.
Conditions Studied
Interventions
- DRUG IDP-118 Lotion
Study Locations (9)
Florida
- Bausch Site 7 - Doral
- Bausch Site 11 - Miami
Other
- Bausch Site 12 - Santo Domingo
- Bausch Site 2 - Panama City
Kentucky
- Bausch Site 3 - Louisville
Missouri
- Bausch Site 6 - Saint Joseph
Nevada
- Bausch Site 1 - Henderson
Texas
- Bausch Site 5 - San Antonio
Utah
- Bausch Site 4 - Murray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2021-03-24 |
| Est. Completion | 2027-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03988439
The ClinicalTrials.gov registry entry for NCT03988439 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (91% lower). The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which IDP-118 Lotion is the first listed.
NCT03988439 reports 9 study locations spanning 7 distinct geographic areas - top geographies include Florida, Other, Kentucky.
Frequently Asked Questions
What is clinical trial NCT03988439 about?
NCT03988439 is a clinical study titled "A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis". This study is to evaluate the safety, the systemic exposure, and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-118 lotion in pediatric participants with moderate to severe plaque psoriasis.
What is the current status of trial NCT03988439?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 45 participants. The study started on 2021-03-24. Estimated completion is 2027-03.
What conditions does trial NCT03988439 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT03988439?
The interventions under investigation include: IDP-118 Lotion (DRUG).
Who is sponsoring clinical trial NCT03988439?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03988439 being conducted?
This trial has 9 study locations across Florida, Kentucky, Missouri, Nevada, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
RECRUITING · Phase 4
-
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
-
Taltz in Combination With Enstilar for Psoriasis
RECRUITING · Phase 4
-
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.